[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"squamous-cell-carcinoma-of-the-oral-cavity\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:squamous-cell-carcinoma-of-the-oral-cavity":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,44,74,100],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":43},"100518430","phase-2-de-intensification-of-postoperative-radiotherapy-in-patients-with-squamous-cell-carcinoma-of-the-head-and-neck-100518430",false,"NCT06030440","De-Intensification of Postoperative Radiotherapy in Patients With Squamous Cell Carcinoma of the Head and Neck","DIREKHT2","Inclusion Criteria:\n\n1. Histologically proven squamous cell carcinoma of the oral cavity\u002Flarynx\u002Foro-or hypopharynx (except glottis cancer (pT1\u002F2pN0))\n2. Surgery of primary tumor and neck dissection performed according to predefined surgical standard\n3. Indication for postoperative radio(chemo)therapy\n4. No lymph node metastases \\> 6cm\n5. Lymph node metastases in not more than 3 lymph node level\n6. No distant metastases (cM0)\n7. Age ≥ 18 years, no upper age limit\n8. Eastern Cooperative Oncology Group (ECOG) ≤ 2\n9. Patients who understood protocol contents and are able to behave according to protocol\n10. Signed study-specific consent form prior to therapy\n11. Start of radiotherapy at least 6 weeks after last tumor-specific surgery (e.g. resection primary tumor, neck dissection, excluded are surgeries according to wound healing complications)\n\nExclusion Criteria:\n\n1. macroscopic incomplete resection R2\n2. Distant metastases (cM1)\n3. Radiologically or histologically proven early recurrence after surgery (time frame from surgery to start of radio(chemo)therapy)\n4. Lymph node metastases in \\> 3 lymph node level\n5. pregnant or lactating\u002Fnursing women\n6. fertile patients that are not willing to use highly effective methods of contraception (per institutional standards) during treatment\n7. Any condition potentially hampering compliance with the study protocol and follow-up schedule\n8. On-treatment participation on other clinical therapeutic trials\n9. Prior tumor-specific therapy any other than surgery (like prior radiotherapy in the head and neck region, prior chemo- or immunotherapy (neoadjuvant\u002Finduction))\n10. Patients who have contraindication for MRI and CT with contrast agent (both)\n11. Prior (\\> 2 months before beginning of radio(chemo)therapy) neck dissection or surgery in the head and neck area affecting lymph drainage\n12. History of another primary malignancy except for malignancy treated with curative intent and with no known active disease ≥5 years before diagnosis of head and neck cancer, adequately treated non-melanoma skin cancer or lentigo maligna without evidence of disease, adequately treated carcinoma in situ without evidence of disease","ALL","18 Years",{"count":19,"type":20},508,"ESTIMATED","INTERVENTIONAL",[23,24],"PHASE2","PHASE3","This randomized, prospective, multicenter phase II\u002FIII trial will study the reduction of radiation volume by eliminating radiotherapy (RT) to the elective neck using strictly defined surgical and radio-oncological standards to reduce radiotherapy-related long-term side effects without affecting locoregional control.",[27,28,29,30],"Squamous Cell Carcinoma of the Oral Cavity","Squamous Cell Carcinoma of the Larynx","Squamous Cell Carcinoma of the Hypopharynx","Squamous Cell Carcinoma of the Oropharynx","RECRUITING","2026-03-11",{"date":34,"type":35},"2026-03-13","ACTUAL",{"date":37,"type":35},"2024-01-26",{"date":39,"type":20},"2033-09",{"name":41,"class":42},"University of Erlangen-Nürnberg Medical School","OTHER",1,{"id":45,"slug":46,"hasResults":11,"nctId":47,"briefTitle":48,"officialTitle":49,"acronym":50,"eligibilityCriteria":51,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":52,"targetDuration":4,"studyType":21,"phases":54,"briefSummary":55,"conditions":56,"keywords":59,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":65,"lastUpdatePostDateStruct":66,"startDateStruct":68,"completionDateStruct":70,"leadSponsor":72,"locationsCount":43},"100377202","phase-2-fluorescence-guided-surgery-using-crgd-zw800-1-in-oral-cancer-100377202","NCT04191460","Fluorescence-guided Surgery Using cRGD-ZW800-1 in Oral Cancer","Guided by Light: Optimizing Surgical Excision of Oral Cancer Using Real-time Fluorescence Imaging","GuidedbyLight","Inclusion Criteria:\n\n1. Patients with biopsy-proven squamous cell carcinoma of the oral cavity, eligible for surgical resection of the primary tumor;\n2. ≥ 18 years of age;\n3. Before patient registration, written informed consent must be given according to ICH\u002FGCP, and national\u002Flocal regulations;\n4. Screening ECG and clinical laboratory test results are within normal limits, or if any are outside of normal limits they are considered to be clinically insignificant.\n\nExclusion Criteria:\n\n1. Previous surgery, chemotherapy or radiotherapy to the oral cavity;\n2. History of a clinically significant allergy or anaphylactic reactions to any of the components of the agent.\n3. Patients pregnant or breastfeeding, lack of effective contraception in male or female patients with reproductive potential;\n4. Patients with renal insufficiency (eGFR\\\u003C60);\n5. Patients with a previous kidney transplantation in the medical history;\n6. Immuno-compromised patients who do not have the ability to respond normally to an infection due to an impaired on weakened immune system, caused by either a pre-existing disease or concomitant medications;\n7. Any condition that the investigator considers to be potentially jeopardizing the patient's well-being or the study objectives.",{"count":53,"type":20},28,[23],"This is a two-staged clinical trial to investigate the feasibility of intraoperative Fluorescence Imaging (FLI) to adequately assess tumor margins in patients with oral cancer using cRGD-ZW800-1.",[57,58,27],"Squamous Cell Carcinoma of the Head and Neck","Oral Cancer",[60,61,62,63,64],"cRGD-ZW800-1","fluorescence-guided surgery","image-guided surgery","fluorescence imaging","cancer","2025-02-25",{"date":67,"type":35},"2025-02-26",{"date":69,"type":35},"2022-07-12",{"date":71,"type":20},"2025-07-01",{"name":73,"class":42},"Erasmus Medical Center",{"id":75,"slug":76,"hasResults":11,"nctId":77,"briefTitle":78,"officialTitle":79,"acronym":80,"eligibilityCriteria":81,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":82,"targetDuration":84,"studyType":85,"phases":4,"briefSummary":86,"conditions":87,"keywords":88,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":90,"lastUpdatePostDateStruct":91,"startDateStruct":93,"completionDateStruct":95,"leadSponsor":97,"locationsCount":99},"100545344","head-and-neck-carcinoma-clinical-research-platform-for-molecular-and-blood-based-biomarkers-treatment-and-outcome-100545344","NCT06380686","Head and Neck Carcinoma Clinical Research Platform for Molecular and Blood-based Biomarkers, Treatment and Outcome","Head and Neck Carcinoma Clinical Research Platform for Molecular and Blood-based","HEAT","Inclusion Criteria:\n\n* Age ≥ 18 years\n* Able to understand and willing to sign written informed consent\n* Histologically or cytologically confirmed squamous cell carcinoma of the head and neck (oral cavity, oropharynx, hypopharynx or larynx)\n* Patients not amenable for curative treatment who receive palliative systemic treatment or best supportive care\n* Informed consent no later than four weeks after start of first-line palliative systemic treatment. For patients receiving \"best supportive care only\": no later than six weeks after diagnosis\u002Frecurrence or metastatic disease\n\nExclusion Criteria: none",{"count":83,"type":20},120,"36 Months","OBSERVATIONAL","Prospective, open, non-interventional, multi-center clinical registry study with the aim to establish a comprehensive research platform reflecting the real-world treatment landscape for recurrent\u002Fmetastatic head and neck tumor patients.",[27,30,29,28],[89],"SCCHN","2024-11-11",{"date":92,"type":35},"2024-11-13",{"date":94,"type":35},"2024-11-07",{"date":96,"type":20},"2030-11",{"name":98,"class":42},"AIO-Studien-gGmbH",2,{"id":101,"slug":102,"hasResults":11,"nctId":103,"briefTitle":104,"officialTitle":105,"acronym":4,"eligibilityCriteria":106,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":107,"enrollmentInfo":108,"targetDuration":4,"studyType":21,"phases":110,"briefSummary":112,"conditions":113,"keywords":4,"overallStatus":115,"whyStopped":4,"lastUpdateSubmitDate":116,"lastUpdatePostDateStruct":117,"startDateStruct":119,"completionDateStruct":121,"leadSponsor":123,"locationsCount":4},"100562892","chg0521-oral-coating-in-patients-with-solid-tissue-tumorrecurrentmetastatic-tscc-100562892","NCT06609070","CHG0521 Oral Coating in Patients with Solid Tissue Tumor\u002FRecurrent\u002FMetastatic TSCC","CHG0521 Oral Coating; TSCC","Inclusion Criteria:\n\n* 1\\. Age range: 18-80 years, encompassing both males and females. 2. Confirmation of tongue squamous cell carcinoma through histopathology or cytology is required.\n\n  3\\. Patients who are deemed unsuitable for surgery, have surgical indications but decline the treatment, or experience relapse and metastasis after surgery with no further surgical options available.\n\n  4\\. No concurrent use of other traditional Chinese medicine orally or externally within the past 3 months.\n\n  5\\. Presence of at least one measurable lesion according to RECIST 1.1 criteria. 6. Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1.\n\n  7\\. Expected survival time should be equal to or greater than 3 months. 8. Liver function indicators: total bilirubin level ≤1.5 times the upper limit of normal (ULN), AST and ALT levels ≤2.5 times ULN (or ≤5 times ULN in case of liver metastasis).\n\n  9.Renal function indicators: serum creatinine (CRE) ≤1.5×ULN and calculated creatinine clearance (using Cockcroft-Gault formula) ≥60 ml\u002Fmin.\n\n  10.The functionality of vital organs should be essentially normal.\n\nExclusion Criteria:\n\n* 1\\. Patients with tongue squamous cell carcinoma who have undergone tumor resection without any residual tumor; 2. Patients with a known allergy to any therapeutic ingredient or a history of hypersensitivity or allergic constitution; 3. Patients who have experienced a severe infection within 4 weeks prior to the first use of the investigational drug, and whose common adverse reaction criteria were graded as \\>2; 4. Patients with a history of immune deficiency, organ transplantation, or allogeneic bone marrow transplantation; 5. Patients currently enrolled in another concurrent clinical study; 6. Pregnant and lactating women.","80 Years",{"count":109,"type":20},30,[111],"NA","This is a prospective single-arm loading test study of CHG0521 oral coating in patients with solid tissue tumor\u002Frecurrent\u002Fmetastatic TSCC",[114,27],"Squamous Cell Carcinoma","NOT_YET_RECRUITING","2024-09-20",{"date":118,"type":35},"2024-09-23",{"date":120,"type":20},"2024-10-15",{"date":122,"type":20},"2026-08-31",{"name":124,"class":42},"Guangzhou University of Traditional Chinese Medicine"]